UCLA researchers from the Department of Medicine have developed novel nanoparticle and imaging methods for the MRI-guided targeted delivery of therapeutic agents.
Magnetic Resonance Imaging (MRI) is a widely used diagnostic imaging platform for both anatomical and functional imaging. MRI is increasingly being used in clinical practice to guide, control, and monitor thermal ablation of diseased tissues by non-invasive high-intensity focused ultrasound (HIFU) or minimally invasive near-infrared (NIR) light inside the MRI scanner. However, MRI-guided delivery of targeted agents remains the subject of early stage exploration.
UCLA researchers have developed novel MRI-guided stimuli-responsive mesoporous silica nanoparticles (MSNs) for targeted delivery of therapeutic agents. New developments in nanoparticle technology have been combined to deliver materials to specific sites of interest at a cellular level, enhance imaging contrast, and enable controlled release of encapsulated agents. With these engineered nanoparticles, MRI can now be used to spatially identify diseased tissue with enhanced dual contrast imaging, and then locally activate the release of therapeutic agents in a controlled signal-targeted manner.
|European Patent Office||Published Application||WO 2020/186268||09/17/2020||2017-846|
Additional Patent Pending
Theranostics, MRI, nanoparticles, drug delivery, high-intensity focused ultrasound, near-infared light, targeted-agent delivery, MRI-guided